Novocure Stock Forecast, Price & News

Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVCR stock has increased by 71.3% and is now trading at $115.39.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novocure.

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Novocure.

Novocure Ltd (NASDAQ:NVCR) released its earnings results on Thursday, July, 30th. The medical equipment provider reported $0.02 EPS for the quarter, topping the consensus estimate of $0.01 by $0.01. The medical equipment provider had revenue of $115.90 million for the quarter, compared to analyst estimates of $105.96 million. Novocure had a net margin of 2.88% and a return on equity of 5.14%. Novocure's revenue was up 33.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.01) earnings per share.
View Novocure's earnings history.

10 equities research analysts have issued 12 month target prices for Novocure's stock. Their forecasts range from $58.00 to $125.00. On average, they anticipate Novocure's stock price to reach $90.67 in the next twelve months. This suggests that the stock has a possible downside of 21.4%.
View analysts' price targets for Novocure.

Novocure saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 5,330,000 shares, an increase of 41.4% from the September 15th total of 3,770,000 shares. Based on an average daily volume of 961,000 shares, the short-interest ratio is currently 5.5 days. Approximately 6.4% of the shares of the stock are short sold.
View Novocure's Short Interest.

Some companies that are related to Novocure include Baxter International (BAX), DexCom (DXCM), ResMed (RMD), FRESENIUS SE &/S (FSNUY), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Penumbra (PEN), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Hill-Rom (HRC), Haemonetics (HAE), Nevro (NVRO), Globus Medical (GMED) and ICU Medical (ICUI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), salesforce.com (CRM) and Square (SQ).

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Novocure's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.41%), Peregrine Capital Management LLC (0.13%), Scout Investments Inc. (0.10%), State of New Jersey Common Pension Fund D (0.06%), Taylor Frigon Capital Management LLC (0.05%) and Hodges Capital Management Inc. (0.04%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for Novocure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, State of New Jersey Common Pension Fund D, CWM LLC, and Envestnet Asset Management Inc.. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for Novocure.

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Hodges Capital Management Inc., Rhenman & Partners Asset Management AB, Eagle Global Advisors LLC, Standard Life Aberdeen plc, IBM Retirement Fund, NewFocus Financial Group LLC, and Avantax Advisory Services Inc..
View insider buying and selling activity for Novocure.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $115.39.

Novocure has a market capitalization of $11.66 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

The official website for Novocure is www.novocure.com.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]